Anixa Biosciences Inc Balance Sheet
ANIX|12 years of annual SEC 10-K data (FY2011-FY2024)
Shows total assets, cash and equivalents, receivables, property and equipment, total debt, and shareholders' equity across 12 fiscal years. All figures from audited SEC 10-K filings.
Anixa Biosciences Inc had $22M in total assets and $20M in shareholders' equity as of FY2024.
Based on SEC 10-K filings.
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score -5.53 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
| Item | FY2024 | FY2023 | FY2022 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | FY2015 | FY2014 | FY2012 | FY2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $1.3M | $915.0K | $12.4M | $6.4M | $3.1M | $3.3M | $2.5M | $4.4M | $3.4M | $898.2K | $774.0K | $1.1M |
| Accounts Receivable | - | - | - | - | - | - | - | - | - | $400.0K | - | - |
| Current Assets | $21.4M | $25.4M | $30.2M | $9.4M | $6.1M | $5.5M | $7.0M | $3.4M | $6.9M | $6.3M | $922.0K | $3.1M |
| PP&E (Net) | - | - | - | - | $200.6K | $72.7K | $52.7K | $156.6K | $43.5K | $11.9K | $10.3K | $15.9K |
| Total Assets | $21.6M | $25.5M | $30.4M | $9.5M | $6.3M | $6.4M | $8.8M | $5.6M | $9.3M | $9.1M | $5.7M | $8.6M |
| Current Liabilities | $2.5M | $2.0M | $2.0M | $1.2M | $1.5M | $1.3M | $889.5K | $468.8K | $593.8K | $1.8M | $1.8M | $2.1M |
| Shareholders' Equity | $20.0M | $24.3M | $29.0M | $8.8M | $5.2M | $5.4M | $7.9M | $5.1M | $4.0M | -$3.3M | $1.1M | $4.6M |